Table 2.
Baseline characteristics
| n | % | ||
|---|---|---|---|
| Age in years, median (range) | 74 (32–94) | - | |
| Sex | Females | 66 | 33.0% |
| Males | 134 | 67.0% | |
| Performance status | 0 | 66 | 33.0% |
| 1 | 73 | 36.5% | |
| 2 | 41 | 20.5% | |
| 3 | 7 | 3.5% | |
| Not known | 13 | 6.5% | |
| Differentiation | Well | 10 | 5.0% |
| Moderate | 121 | 60.5% | |
| Poor | 6 | 3.0% | |
| Not known | 63 | 31.5% | |
| Tumour stage (pre-treatment) |
cT1 | 21 | 10.5% |
| cT2 | 89 | 44.5% | |
| cT3 | 87 | 43.5% | |
| cT4 | 3 | 1.5% | |
| Nodal stage | cN0 | 125 | 62.5% |
| cN1 | 56 | 28.0% | |
| cN2 | 18 | 9.0% | |
| Not known | 1 | 0.5% | |
| Metastases stage | M0 | 200 | 100% |
| Distance from anal verge | <7 cm | 144 | 72.0% |
| 7–11 cm | 47 | 23.5% | |
| >11 cm | 2 | 1.0% | |
| Not recorded | 7 | 3.5% | |
| Tumour size | ≤3 cm | 107 | 53.5% |
| >3 cm | 65 | 32.5% | |
| Not recorded | 28 | 14.0% |